ReNeuron Group plc Presents positive exosome data at major conference (4700F)

TIDMRENE

RNS Number : 4700F

ReNeuron Group plc

18 May 2017

 
 AIM: RENE     18 May 
                2017 
 

ReNeuron Group plc

ReNeuron presents positive pre-clinical data with its ExoPr0 exosome therapy candidate at major scientific conference

Data show that ExoPr0 can cross the blood brain barrier and can potentially target multiple diseases via local or systemic administration

ReNeuron Group plc (the "Company") (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that it will be presenting new positive pre-clinical data relating to its ExoPr0 CTX cell-derived exosome therapy candidate at a leading scientific conference.

In this poster presentation, ReNeuron researchers will describe studies undertaken to investigate the in vivo biodistribution of ExoPr0, using the most common and disease applicable routes of administration to deliver the exosomes. The studies showed that ExoPr0 can be targeted to specific organs and tissues by either local or systemic administration. The uptake of ExoPr0 by particular cell types in target organs suggests that there also may be some specificity in uptake at the cellular level.

ReNeuron has identified the potential of ExoPr0 as both a novel therapeutic candidate and as a drug delivery vehicle, based on earlier research to demonstrate the ability of ExoPr0 to modulate fibroblasts, immune cells and cancer cell lines in vitro. This earlier work, together with these new findings showing that ExoPr0 can be targeted to specific tissues and organs and, most importantly, can penetrate the blood brain barrier, suggest that there is significant potential to develop ExoPr0 for the treatment of multiple diseases.

The above findings are being presented today at the International Society for Extracellular Vesicles (ISEV) 2017 Annual Meeting in Toronto, Canada. Further information about this conference may be found at www.isev.org/page/ISEV2017

Dr Randolph Corteling, Head of Research at ReNeuron, said:

"We are very encouraged by the findings being presented at the ISEV 2017 conference relating to our ExoPr0 exosome therapy candidate. The ability to target ExoPr0 to specific tissues and organs, including the brain, via clinically relevant routes of administration is highly significant. This, together with other recent positive data we have presented relating to the characterisation and scale-up potential of our exosome therapy candidates, clearly demonstrate the potential of this novel therapeutic platform to target multiple diseases."

ENDS

ENQUIRIES:

 
ReNeuron                                                            [phone] 
Olav Hellebø, Chief Executive Officer 
Michael Hunt, Chief Financial Officer 
Buchanan                                                            [phone] 
Mark Court, Sophie Cowles, Stephanie Watson 
 
Stifel Nicolaus Europe Limited                                      [phone] 
Jonathan Senior, Stewart Wallace, Ben Maddison (NOMAD and Broker) 
 

About ReNeuron

ReNeuron is a leading, clinical-stage cell therapy development company. Based in the UK, its primary objective is the development of novel cell-based therapies targeting areas of significant unmet or poorly met medical need.

ReNeuron has used its unique stem cell technologies to develop cell-based therapies for significant disease conditions where the cells can be readily administered "off-the-shelf" to any eligible patient without the need for additional immunosuppressive drug treatments. The Company has therapeutic candidates in clinical development for motor disability as a result of stroke, for critical limb ischaemia and for the blindness-causing disease, retinitis pigmentosa.

ReNeuron is also advancing its proprietary exosome technology platform as a potential new nanomedicine targeting cancer and as a potential delivery system for gene therapy treatments.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. Further information on ReNeuron and its products can be found at www.reneuron.com.

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RESGGUWUAUPMGQM

(END) Dow Jones Newswires

May 18, 2017 02:00 ET (06:00 GMT)